name: poly(A) RNA polymerase, mitochondrial isoform h2 (human)

description: A poly(A) RNA polymerase, mitochondrial (human) that is a translation product of some mRNA whose exon structure and start site selection renders it capable of giving rise to a protein with the amino acid sequence represented by UniProtKB:Q9NVV4-2.


activated factor Xa heavy chain (human)

An activated factor Xa heavy chain in human. UniProtKB:P00742, 235-488.


name: elongation factor 1-delta isoform 3 (human)

description: An elongation factor 1-delta isoform 3 that is encoded in the genome of human.


name: thymidine phosphorylase isoform h2 (human)

description: A thymidine phosphorylase (human) that is a translation product of some mRNA whose exon structure and start site selection renders it capable of giving rise to a protein with the amino acid sequence represented by UniProtKB:P19971-2.


name: THO complex subunit 5 homolog isoform 1 (human)

description: A THO complex subunit 5 isoform 1 that is encoded in the genome of human.


name: THO complex subunit 5 homolog deaminated 1 (human)

description: A THO complex subunit 5 homolog (human) that has been deaminated on the residue at the position equivalent to Gln-141 of the amino acid sequence represented by UniProtKB:Q13769. UniProtKB:Q13769, Gln-141, MOD:00685.


name: THO complex subunit 5 homolog methylated 1 (human)

description: A THO complex subunit 5 homolog (human) that has been methylated on the residue at the position equivalent to Cys-630 of the amino acid sequence represented by UniProtKB:Q13769. UniProtKB:Q13769, Cys-630, MOD:00660.


name: THO complex subunit 5 homolog phosphorylated 1 (human)

description: A THO complex subunit 5 homolog (human) that has been phosphorylated at Tyr-225. UniProtKB:Q13769, Tyr-225, MOD:00048.


name: THO complex subunit 5 homolog, initiator methionine removed form (human)

description: A THO complex subunit 5 homolog (human) that has had the initiator methionine removed. UniProtKB:Q13769, 2-683.


name: THO complex subunit 5 homolog, initiator methionine removed phosphotyrosine form (human)

description: A THO complex subunit 5 homolog (human) that has had the initiator methionine removed and that includes at least 1 phosphorylated tyrosine. UniProtKB:Q13769, 2-683, MOD:00048.


name: chondroitin sulfate synthase 3 O-glycosylated 2 (human)

description: A chondroitin sulfate synthase 3 (human) that has been O-glycosylated at the residue equivalent to Thr-122 of the amino acid sequence represented by UniProtKB:Q70JA7-1, in which the glycan composition is represented by GlyTouCan:G43417UB. Example: UniProtKB:Q70JA7-1, Thr-122, MOD:00005~GNO:G43417UB.


name: serine/threonine-protein kinase N3 phosphorylated 1 (human)

description: A serine/threonine-protein kinase N3 (human) that has been phosphorylated on the residue at the position equivalent to Thr-718 of the amino acid sequence represented by UniProtKB:Q6P5Z2. UniProtKB:Q6P5Z2, Thr-718, MOD:00047.


name: fructose-bisphosphate aldolase A deaminated 4 (human)

description: A fructose-bisphosphate aldolase A (human) that has been deaminated on the residue at the position equivalent to Asn-181 of the amino acid sequence represented by UniProtKB:P04075-1. Example: UniProtKB:P04075-1, Asn-181, MOD:00684.


dapper homolog 2 isoform h2 (human)

A dapper homolog 2 (human) that is a translation product of some mRNA whose exon structure and start site selection renders it capable of giving rise to a protein with the amino acid sequence represented by UniProtKB:Q5SW24-2.


name: iodotyrosine deiodinase 1 isoform h1 (human)

description: An iodotyrosine deiodinase 1 (human) that is a translation product of some mRNA whose exon structure and start site selection renders it capable of giving rise to a protein with the amino acid sequence represented by UniProtKB:Q6PHW0-1.


vimentin deaminated 5 (human)

A vimentin (human) that has been deaminated on the residue at the position equivalent to Gln-228 of the amino acid sequence represented by UniProtKB:P08670. UniProtKB:P08670, Gln-228, MOD:00685.


name: sulfite oxidase, mitochondrial, transit peptide removed form (human)

description: A sulfite oxidase, mitochondrial (human) that has had the transit peptide removed. UniProtKB:P51687, 80-545.


name: tissue-type plasminogen activator N-glycosylated 16 (human)

description: A tissue-type plasminogen activator (human) that has been N-glycosylated at the residue equivalent to Asn-152 of the amino acid sequence represented by UniProtKB:P00750-1, in which the glycan structure is represented by GlyTouCan:G77038WW. Example: UniProtKB:P00750-1, Asn-152, MOD:00160~GNO:G77038WW.


name: Ral guanine nucleotide dissociation stimulator-like 1 isoform B (human)

description: A Ral guanine nucleotide dissociation stimulator-like 1 (human) that is a translation product of some mRNA whose exon structure and start site selection renders it capable of giving rise to a protein with the amino acid sequence represented by UniProtKB:Q9NZL6-2.


name: Ral guanine nucleotide dissociation stimulator-like 1 isoform A (human)

description: A Ral guanine nucleotide dissociation stimulator-like 1 isoform 1 that is encoded in the genome of human.


name: isoleucine--tRNA ligase, cytoplasmic methylated 1 (human)

description: An isoleucine--tRNA ligase, cytoplasmic (human) that has been methylated on the residue at the position equivalent to Cys-336 of the amino acid sequence represented by UniProtKB:P41252. UniProtKB:P41252, Cys-336, MOD:00660.


name: extracellular matrix organizing protein FRAS1 isoform h5 (human)

description: An extracellular matrix organizing protein FRAS1 (human) that is a translation product of some mRNA whose exon structure and start site selection renders it capable of giving rise to a protein with the amino acid sequence represented by UniProtKB:Q86XX4-5.


name: BRISC complex subunit Abraxas 2 isoform 1 (human)

description: A BRISC complex subunit Abraxas 2 isoform 1 that is encoded in the genome of human.


name: BRISC complex subunit Abro1 isoform 1 (mouse)

description: A BRISC complex subunit Abraxas 2 isoform 1 that is encoded in the genome of mouse.


name: mast/stem cell growth factor receptor Kit sequence variant V560G, signal peptide removed form (human)

description: A mast/stem cell growth factor receptor Kit (human) that has a Gly residue at the position equivalent to Val-560 of the amino acid sequence represented by UniProtKB:P10721-1 and that has had the signal peptide removed. Example: UniProtKB:P10721-1, 26-976, Val-560, CHEBI:29947.


aminodiol

An amino alcohol having two hydroxy functional groups.


A 2-aminooctadecene-1,3-diol having its double bond at position 4.


An aminodiol composed of any octadecene having hydroxy functional groups at positions 1 and 3 and an amino substituent at position 2.


sphingenine

A 2-aminooctadecene-1,3-diol having (2S,3R)-configuration.


A sphingenine in which the C=C double bond is located at the 4-position.


An aminodiol that is octadecane bearing two hydroxy substituents at positions 1 and 3 as well as an amino substituent at position 2.


name: corrinoid adenosyltransferase MMAB sequence variant R186W, transit peptide removed form (human)

description: A corrinoid adenosyltransferase MMAB (human) that has a Trp residue at the position equivalent to Arg-186 of the amino acid sequence represented by UniProtKB:Q96EY8 and that has had the transit peptide removed. UniProtKB:Q96EY8, 33-250, Arg-186, CHEBI:29954.


corrinoid adenosyltransferase MMAB

A protein that is a translation product of the human MMAB gene or a 1:1 ortholog thereof.


name: corrinoid adenosyltransferase MMAB sequence variant R191W, transit peptide removed form (human)

description: A corrinoid adenosyltransferase MMAB (human) that has a Trp residue at the position equivalent to Arg-191 of the amino acid sequence represented by UniProtKB:Q96EY8 and that has had the transit peptide removed. UniProtKB:Q96EY8, 33-250, Arg-191, CHEBI:29954.


name: corrinoid adenosyltransferase MMAB sequence variant E193L, transit peptide removed form (human)

description: A corrinoid adenosyltransferase MMAB (human) that has a Leu residue at the position equivalent to Glu-193 of the amino acid sequence represented by UniProtKB:Q96EY8 and that has had the transit peptide removed. UniProtKB:Q96EY8, 33-250, Glu-193, CHEBI:30006.


name: corrinoid adenosyltransferase MMAB, transit peptide removed form (human)

description: A corrinoid adenosyltransferase MMAB (human) that has had the transit peptide removed. UniProtKB:Q96EY8, 33-250.


name: 5-hydroxytryptamine receptor 2A isoform h2 (human)

description: A 5-hydroxytryptamine receptor 2A (human) that is a translation product of some mRNA whose exon structure and start site selection renders it capable of giving rise to a protein with the amino acid sequence represented by UniProtKB:P28223-2.


haptoglobin N-glycosylated 8 (human)

A haptoglobin (human) that has been N-glycosylated at the residue equivalent to Asn-184 of the amino acid sequence represented by UniProtKB:P00738-1, in which the glycan structure is represented by GlyTouCan:G31118FR. Example: UniProtKB:P00738-1, Asn-184, MOD:00160~GNO:G31118FR.


Breast Carcinoma Metastatic in the Lung

category: biolink:Disease biolink:DiseaseOrPhenotypicFeature biolink:BiologicalEntity biolink:ThingWithTaxon biolink:NamedThing

description: A carcinoma that arises from the breast and has metastasized to the lung.


arenesulfonic acid

Organic derivatives of sulfonic acid in which the sulfo group is linked directly to carbon of an aryl group.


name: coagulation factor X N-glycosylated 2 (human)

description: A coagulation factor X (human) that has been N-glycosylated at the residue equivalent to Asn-221 of the amino acid sequence represented by UniProtKB:P00742-1, in which the glycan structure is represented by GlyTouCan:G24501HF. Example: UniProtKB:P00742-1, Asn-221, MOD:00160~GNO:G24501HF.


name: interferon gamma isoform 1, signal peptide removed N-glycosylated 1 (human)

description: An interferon gamma isoform 1, signal peptide removed glycosylated form in human in which N-linked glycosylation occurs at Asn-48 and Asn-120. UniProtKB:P01579-1, 24-157, Asn-48/Asn-120, MOD:00160.


name: mothers against decapentaplegic homolog 4 sequence variant Q455* (human)

description: A mothers against decapentaplegic homolog 4 (human) that has has been truncated after the position equivalent to Ala-454 of the amino acid sequence represented by UniProtKB:Q13485. UniProtKB:Q13485, 1-454.


name: phosphatidylinositol N-acetylglucosaminyltransferase subunit Y isoform 1 (human)

description: A phosphatidylinositol N-acetylglucosaminyltransferase subunit Y isoform 1 that is encoded in the genome of human.


integrin beta-7 isoform Short (human)

An integrin beta-7 (human) that is a translation product of some mRNA whose exon structure and start site selection renders it capable of giving rise to a protein with the amino acid sequence represented by UniProtKB:P26010-2.


name: integrin beta-7 isoform 1, signal peptide removed form (human)

description: An integrin beta-7 isoform 1, signal peptide removed form in human. UniProtKB:P26010-1, 20-798.


integrin beta-7 deaminated 1 (human)

An integrin beta-7 (human) that has been deaminated on the residue at the position equivalent to Asn-434 of the amino acid sequence represented by UniProtKB:P26010-1. Example: UniProtKB:P26010-1, Asn-434, MOD:00684.


integrin beta-7 isoform 1 (human)

An integrin beta-7 isoform 1 that is encoded in the genome of human.


integrin beta-7 methylated 2 (human)

An integrin beta-7 (human) that has been methylated on the residue at the position equivalent to Cys-537 of the amino acid sequence represented by UniProtKB:P26010-1. Example: UniProtKB:P26010-1, Cys-537, MOD:00660.


integrin beta-7 methylated 5 (human)

An integrin beta-7 (human) that has been methylated on the residue at the position equivalent to Cys-271 of the amino acid sequence represented by UniProtKB:P26010-1. Example: UniProtKB:P26010-1, Cys-271, MOD:00660.


integrin beta-7 methylated 1 (human)

An integrin beta-7 (human) that has been methylated on the residue at the position equivalent to Cys-654 of the amino acid sequence represented by UniProtKB:P26010-1. Example: UniProtKB:P26010-1, Cys-654, MOD:00660.


integrin beta-7 methylated 3 (human)

An integrin beta-7 (human) that has been methylated on the residue at the position equivalent to Cys-670 of the amino acid sequence represented by UniProtKB:P26010-1. Example: UniProtKB:P26010-1, Cys-670, MOD:00660.


integrin beta-7 methylated 4 (human)

An integrin beta-7 (human) that has been methylated on the residue at the position equivalent to Cys-448 of the amino acid sequence represented by UniProtKB:P26010-1. Example: UniProtKB:P26010-1, Cys-448, MOD:00660.


serine incorporator 1

A protein that is a translation product of the human SERINC1 gene or a 1:1 ortholog thereof.


name: serine incorporator 1 cysteinylated 1 (human)

description: A serine incorporator 1 (human) that has been cysteinylated on the residue at the position equivalent to Cys-193 of the amino acid sequence represented by UniProtKB:Q9NRX5. UniProtKB:Q9NRX5, Cys-193, MOD:00765.


name: serine incorporator 1 deaminated 1 (human)

description: A serine incorporator 1 (human) that has been deaminated on the residue at the position equivalent to Asn-33 of the amino acid sequence represented by UniProtKB:Q9NRX5. UniProtKB:Q9NRX5, Asn-33, MOD:00684.


serine incorporator 1 isoform 1 (human)

A serine incorporator 1 isoform 1 that is encoded in the genome of human.


name: serine incorporator 1, initiator methionine removed form (human)

description: A serine incorporator 1 (human) that has had the initiator methionine removed. UniProtKB:Q9NRX5, 2-453.


name: RAF proto-oncogene serine/threonine-protein kinase isoform 1 phosphorylated 3 (human)

description: A RAF proto-oncogene serine/threonine-protein kinase isoform 1 phosphorylated 3 in human. UniProtKB:P04049-1, Ser-259/Ser-621, MOD:00046.


name: RAF proto-oncogene serine/threonine-protein kinase isoform 1 (human)

description: A RAF proto-oncogene serine/threonine-protein kinase isoform 1 that is encoded in the genome of human.


name: RAF proto-oncogene serine/threonine-protein kinase isoform 1 phosphorylated 2 (human)

description: A RAF proto-oncogene serine/threonine-protein kinase isoform 1 phosphorylated 2 in human. UniProtKB:P04049-1, Ser-338/Ser-339, MOD:00046.


name: RAS guanyl-releasing protein 1 isoform h2 (human)

description: A RAS guanyl-releasing protein 1 (human) that is a translation product of some mRNA whose exon structure and start site selection renders it capable of giving rise to a protein with the amino acid sequence represented by UniProtKB:O95267-2.


name: DNA repair protein complementing XP-C cells isoform h2 (human)

description: A DNA repair protein complementing XP-C cells (human) that is a translation product of some mRNA whose exon structure and start site selection renders it capable of giving rise to a protein with the amino acid sequence represented by UniProtKB:Q01831-2.


name: versican core protein O-glycosylated 117 (human)

description: A versican core protein (human) that has been O-glycosylated at the residue equivalent to Thr-1569 of the amino acid sequence represented by UniProtKB:P13611-1, in which the glycan composition is represented by GlyTouCan:G43417UB. Example: UniProtKB:P13611-1, Thr-1569, MOD:00005~GNO:G43417UB.


L-threo-isocitric acid

The (1S,2R)-stereoisomer of isocitric acid.


A 1,2-diacyl-sn-glycerol in which the 1-acyl group is specified as oleoyl.


2-acylglycerol 22:4

A 2-monoglyceride in which the acyl group contains 22 carbons and 4 double bonds.


monoacylglycerol 22:4

A monoglyceride in which the acyl groups contain a total of 22 carbons and 4 double bonds


1-acylglycerol 22:4

A 1-monoglyceride in which the acyl group contains 22 carbons and 4 double bonds.


name: immunoglobulin heavy constant mu isoform h1 N-glycosylated 70 (human)

description: An immunoglobulin heavy constant mu isoform h1 (human) that has been N-glycosylated at the residue equivalent to Asn-440 of the amino acid sequence represented by UniProtKB:P01871-1, in which the glycan composition is represented by GlyTouCan:G41247ZX. UniProtKB:P01871-1, Asn-440, MOD:00160~GNO:G41247ZX.


name: versican core protein O-glycosylated 219 (human)

description: A versican core protein (human) that has been O-glycosylated at the residue equivalent to Thr-2887 of the amino acid sequence represented by UniProtKB:P13611-1, in which the glycan composition is represented by GlyTouCan:G43417UB. Example: UniProtKB:P13611-1, Thr-2887, MOD:00005~GNO:G43417UB.


name: ATP-dependent RNA helicase A deaminated 3 (human)

description: An ATP-dependent RNA helicase A (human) that has been deaminated on the residue at the position equivalent to Asn-311 of the amino acid sequence represented by UniProtKB:Q08211-1. Example: UniProtKB:Q08211-1, Asn-311, MOD:00684.


name: low-density lipoprotein receptor, signal peptide removed form (human)

description: A low-density lipoprotein receptor (human) that has had the signal peptide removed. UniProtKB:P01130, 22-860.


name: TGF-beta receptor type-2 sequence variant N435S (human)

description: A TGF-beta receptor type-2 (human) that has a Ser residue at the position equivalent to Asn-435 of the amino acid sequence represented by UniProtKB:P37173-1. Example: UniProtKB:P37173-1, Asn-435, CHEBI:29999.


name: diacylglycerol kinase delta isoform h2 (human)

description: A diacylglycerol kinase delta (human) that is a translation product of some mRNA whose exon structure and start site selection renders it capable of giving rise to a protein with the amino acid sequence represented by UniProtKB:Q16760-1.


name: sodium-dependent neutral amino acid transporter B(0)AT1 sequence variant D173N (human)

description: A sodium-dependent neutral amino acid transporter B(0)AT1 (human) that has an Asn residue at the position equivalent to Asp-173 of the amino acid sequence represented by UniProtKB:Q695T7. UniProtKB:Q695T7, Asp-173, CHEBI:50347.


name: sodium-dependent neutral amino acid transporter B(0)AT1 sequence variant S303L (human)

description: A sodium-dependent neutral amino acid transporter B(0)AT1 (human) that has a Leu residue at the position equivalent to Ser-303 of the amino acid sequence represented by UniProtKB:Q695T7. UniProtKB:Q695T7, Ser-303, CHEBI:30006.


name: sodium-dependent neutral amino acid transporter B(0)AT1 isoform 1 (human)

description: A sodium-dependent neutral amino acid transporter B(0)AT1 isoform 1 that is encoded in the genome of human.


name: immunoglobulin heavy constant mu N-glycosylated 30 (human)

description: An immunoglobulin heavy constant mu (human) that has been N-glycosylated at the residue equivalent to Asn-272 of the amino acid sequence represented by UniProtKB:P01871-2, in which the glycan composition is represented by GlyTouCan:G12580WI. Example: UniProtKB:P01871-2, Asn-272, MOD:00160~GNO:G12580WI.


phosphopentomutase isoform h1 (human)

A phosphopentomutase (human) that is a translation product of some mRNA whose exon structure and start site selection renders it capable of giving rise to a protein with the amino acid sequence represented by UniProtKB:Q96G03-1.


name: proto-oncogene tyrosine-protein kinase Src phosphorylated 1 (human)

description: A proto-oncogene tyrosine-protein kinase Src (human) that has been phosphorylated on the residue at the position equivalent to Ser-75 of the amino acid sequence represented by UniProtKB:P12931-1. Example: UniProtKB:P12931-1, Ser-75, MOD:00046.


name: ribosomal protein S6 kinase alpha-3 phosphorylated 4 (human)

description: A ribosomal protein S6 kinase alpha-3 (human) that has been phosphorylated on the residue at the position equivalent to Ser-227 of the amino acid sequence represented by UniProtKB:P51812. UniProtKB:P51812, Ser-227, MOD:00046.


name: protein-lysine 6-oxidase N-glycosylated 1 (human)

description: A protein-lysine 6-oxidase (human) that has been N-glycosylated at the residue equivalent to Asn-144 of the amino acid sequence represented by UniProtKB:P28300-1, in which the glycan composition is represented by GlyTouCan:G92050GC. Example: UniProtKB:P28300-1, Asn-144, MOD:00160~GNO:G92050GC.


name: ubiquitin carboxyl-terminal hydrolase 5 isoform Long (human)

description: A ubiquitin carboxyl-terminal hydrolase 5 isoform 1 that is encoded in the genome of human.


N-alpha-acetyltransferase 60

A protein that is a translation product of the human NAA60 gene or a 1:1 ortholog thereof.


name: N-alpha-acetyltransferase 60 isoform 1 (human)

description: An N-alpha-acetyltransferase 60 isoform 1 that is encoded in the genome of human.


name: N-alpha-acetyltransferase 60 isoform h5 (human)

description: An N-alpha-acetyltransferase 60 (human) that is a translation product of some mRNA whose exon structure and start site selection renders it capable of giving rise to a protein with the amino acid sequence represented by UniProtKB:Q9H7X0-5.


name: N-alpha-acetyltransferase 60 isoform h4 (human)

description: An N-alpha-acetyltransferase 60 (human) that is a translation product of some mRNA whose exon structure and start site selection renders it capable of giving rise to a protein with the amino acid sequence represented by UniProtKB:Q9H7X0-4.


name: N-alpha-acetyltransferase 60 isoform h2 (human)

description: An N-alpha-acetyltransferase 60 (human) that is a translation product of some mRNA whose exon structure and start site selection renders it capable of giving rise to a protein with the amino acid sequence represented by UniProtKB:Q9H7X0-2.


name: N-alpha-acetyltransferase 60 isoform h3 (human)

description: An N-alpha-acetyltransferase 60 (human) that is a translation product of some mRNA whose exon structure and start site selection renders it capable of giving rise to a protein with the amino acid sequence represented by UniProtKB:Q9H7X0-3.


prosaposin N-glycosylated 6 (human)

A prosaposin (human) that has been N-glycosylated at the residue equivalent to Asn-101 of the amino acid sequence represented by UniProtKB:P07602-1, in which the glycan composition is represented by GlyTouCan:G27622TD. Example: UniProtKB:P07602-1, Asn-101, MOD:00160~GNO:G27622TD.


name: nuclear receptor coactivator 3 methylated 1 (human)

description: A nuclear receptor coactivator 3 (human) that has been methylated on the residue at the position equivalent to Arg-1163 of the amino acid sequence represented by UniProtKB:Q9Y6Q9-1. Example: UniProtKB:Q9Y6Q9-1, Arg-1163, MOD:00658.


urocanate hydratase isoform 1 (human)

A urocanate hydratase isoform 1 that is encoded in the genome of human.


urocanate hydratase isoform h2 (human)

A urocanate hydratase (human) that is a translation product of some mRNA whose exon structure and start site selection renders it capable of giving rise to a protein with the amino acid sequence represented by UniProtKB:Q96N76-2.


name: histone H2A type 2-B, initiator methionine removed asymmetrically-dimethylated 2 (human)

description: A histone H2A type 2-B (human) that has had the initiator methionine removed and has been post-translationally modified to include asymmetric dimethyl-L-arginine at position 12 of the amino acid sequence represented by UniProtKB:Q8IUE6. UniProtKB:Q8IUE6, 2-130, Arg-12, MOD:00077.


name: histone H2A type 2-A, initiator methionine removed dimethylated 1 (human)

description: A histone H2A type 2-A (human) that has had the initiator methionine removed and that has been dimethylated at the position equivalent to Arg-4 of the amino acid sequence represented by UniProtKB:Q6FI13. UniProtKB:Q6FI13, 2-130, Arg-4, MOD:00783.


name: Stage IIA Lung Small Cell Carcinoma AJCC v7

description: Stage IIA includes: (T2b, N0, M0); (T1a, N1, M0); (T1b, N1, M0); (T2a, N1, M0).  T2b: Lung cancer with a tumor size more than 5 cm but 7 cm or less in greatest dimension.  T1a: Lung cancer with a tumor size of 2 cm or less in greatest dimension, surrounded by lung or visceral pleura and without bronchoscopic evidence of invasion more proximal than the lobar bronchus (i.e., not in the main bronchus). The uncommon superficial tumor of any size with its invasive component limited to the bronchial wall, which may extend proximal to the main bronchus, is also classified as T1a.  T1b: Lung cancer with a tumor size more than 2 cm but 3 cm or less in greatest dimension, surrounded by lung or visceral pleura and without bronchoscopic evidence of invasion more proximal than the lobar bronchus (i.e., not in the main bronchus).  T2a: Lung cancer with a tumor size more than 3 cm but 5 cm or less in greatest dimension.  N0: No regional lymph node metastasis.  N1: Lung cancer with metastasis in ipsilateral peribronchial and/or ipsilateral hilar lymph nodes and intrapulmonary lymph nodes, including involvement by direct extension. M0: No distant metastasis. (AJCC 7th ed.)


neoplasm of thorax

description: A neoplasm (disease) that involves the thoracic segment of trunk.


Stage IVB Lung Cancer AJCC v8

description: Stage IVB includes: Any T, Any N, M1c. M1c: Tumor with multiple extrathoracic metastases in a single organ or in multiple organs. (AJCC 8th ed.)


Advanced Bronchogenic Carcinoma

description: Bronchogenic carcinoma that has spread extensively to other anatomic sites or is no longer responding to treatment.


Lung squamous cell carcinoma stage I

description: Stage I includes: IA: (T1a, N0, M0); (T1b, N0, M0) and IB: (T2a, N0, M0).  T1a: Lung cancer with a tumor size of 2 cm or less n greatest dimension, surrounded by lung or visceral pleura and without bronchoscopic evidence of invasion more proximal than the lobar bronchus (i.e., not in the main bronchus). The uncommon superficial tumor of any size with its invasive component limited to the bronchial wall, which may extend proximal to the main bronchus, is also classified as T1a.  T1b: Lung cancer with a tumor size more than 2 cm but 3 cm or less in greatest dimension, surrounded by lung or visceral pleura and without bronchoscopic evidence of invasion more proximal than the lobar bronchus (i.e., not in the main bronchus).  T2a: Lung cancer with a tumor size more than 3 cm but 5 cm or less in greatest dimension.  N0: No regional lymph metastasis.  M0: No distant metastasis. (AJCC 7th ed.)


name: Stage IIA Lung Squamous Cell Carcinoma AJCC v7


Lung Adenocarcinoma by AJCC v7 Stage

description: A term that refers to the staging of lung adenocarcinoma, following the rules of the TNM AJCC v7 classification system.


Lung Secretory Carcinoma

description: A rare carcinoma that arises from the lung and has histopathological, immunohistochemical, and genetic features identical to those described in breast and salivary gland secretory carcinomas.


name: Stage IA Lung Small Cell Carcinoma AJCC v7

description: Stage IA includes: (T1a, N0, M0); (T1b, N0, M0).  T1a: Lung cancer with a tumor size of 2 cm or less in greatest dimension, surrounded by lung or visceral pleura and without bronchoscopic evidence of invasion more proximal than the lobar bronchus (i.e., not in the main bronchus). The uncommon superficial tumor of any size with its invasive component limited to the bronchial wall, which may extend proximal to the main bronchus, is also classified as T1a.  T1b: Lung cancer with a tumor size more than 2 cm but 3 cm or less in greatest dimension, surrounded by lung or visceral pleura and without bronchoscopic evidence of invasion more proximal than the lobar bronchus (i.e., not in the main bronchus).  N0: No regional lymph metastasis.  M0: No distant metastasis. (AJCC 7th ed.)


Small cell lung cancer limited stage

description: Small cell lung carcinoma which is confined to one hemi-thorax and the regional lymph nodes.


neuroendocrine carcinoma of lung

description: A high grade malignant neoplasm that arises from the lung and is characterized by the presence of malignant neuroendocrine cells.  This category includes small cell lung carcinoma, large cell lung neuroendocrine carcinoma, and combined lung carcinoma.


Non-small cell lung cancer stage IIIB

description: Stage IIIB includes: (T1a, N3, M0); (T1b, N3, M0); (T2a, N3, M0); (T2b, N3, M0); (T3, N3, M0); (T4, N2, M0); (T4, N3, M0).  T4: Lung cancer with a tumor of any size that invades any of the following: mediastinum, heart, great vessels, trachea, recurrent laryngeal nerve, esophagus, vertebral body, carina, and separate tumor nodule(s) in a different ipsilateral lobe.  N2: Lung cancer with metastasis to ipsilateral mediastinal and/or subcarinal lymph nodes.  N3: Lung cancer with metastasis to contralateral mediastinal, contralateral hilar, ipsilateral or contralateral scalene, or supraclavicular lymph nodes.  M0: No distant metastasis. (AJCC 7th ed.)


name: Transformed EGFR-Positive Lung Adenocarcinoma to Squamous Cell Carcinoma

description: Histologic transformation of EGFR mutation-positive lung adenocarcinoma to squamous cell carcinoma, following treatment with tyrosine kinase inhibitors.


Metastatic non-small cell lung cancer

description: Stage IV includes: (Any T, Any N, M1a); (Any T, Any N, M1b).  M1a: Lung cancer with separate tumor nodule(s) in a contralateral lobe; tumor with pleural nodules or malignant pleural (or pericardial) effusion.  M1b: Distant metastasis. (AJCC 7th ed.)


name: Stage IIIA Lung Squamous Cell Carcinoma AJCC v7

description: Stage IIIA includes: (T1a, N2, M0); (T1b, N2, M0); (T2a, N2, M0); (T2b, N2, M0); (T3, N1, M0); (T3, N2, M0); (T4, N0, M0); (T4, N1, M0).  T4: Lung cancer with a tumor of any size that invades any of the following: mediastinum, heart, great vessels, trachea, recurrent laryngeal nerve, esophagus, vertebral body, carina, and separate tumor nodule(s) in a different ipsilateral lobe.  N1: Lung cancer with metastasis in ipsilateral peribronchial and/or ipsilateral hilar lymph nodes and intrapulmonary lymph nodes, including involvement by direct extension.  N2: Lung cancer with metastasis to ipsilateral mediastinal and/or subcarinal lymph nodes.  M0: No distant metastasis. (AJCC 7th ed.)


Stage I Lung Cancer AJCC v8

description: Stage I includes: IA1: (T1mi, N0, M0); (T1a, N0, M0); IA2: (T1b, N0, M0); IA3: (T1c, N0, M0); IB: (T2a, N0, M0). T1mi: Minimally invasive adenocarcinoma: adenocarcinoma (3 cm or less in greatest dimension) with a predominantly lepidic pattern and 5 mm or less invasion in greatest dimension. T1a: Tumor measuring 1 cm or less in greatest dimension. A superficial, spreading tumor of any size whose invasive component is limited to the bronchial wall and may extend proximal to the main bronchus also is classified as T1a, but these tumors are uncommon. T1b: Tumor measuring more than 1 cm but 2 cm or less in greatest dimension. T1c: Tumor measuring more than 2 cm but 3 cm or less in greatest dimension. T2a: Tumor measuring more than 3 cm but 4 cm or less in greatest dimension. N0: No regional lymph node metastases. M0: No distant metastasis. (AJCC 8th ed.)


Advanced Lung Adenosquamous Carcinoma

description: Lung adenosquamous carcinoma that has spread extensively to other anatomic sites or is no longer responding to treatment.


Lung Micropapillary Adenocarcinoma

description: An aggressive variant of lung adenocarcinoma that exhibits a micropapillary architectural pattern. The prognosis is usually poor.


Invasive Lung Mucinous Adenocarcinoma

description: An invasive adenocarcinoma that arises from the lung. It is characterized by the presence of tall columnar cells and mucin production. This category refers to cases formerly classified as mucinous bronchioloalveolar carcinoma, excluding cases that meet the criteria for adenocarcinoma in situ or mucinous minimally invasive adenocarcinoma.


Lung Spindle Cell Carcinoma

description: A morphologic variant of sarcomatoid carcinoma characterized by the presence of malignant spindle cells and focal lymphoplasmacytic infiltrates.  Adenocarcinoma cells, malignant squamous cells, and giant cells are not present.


name: Locally Advanced Lung Non-Small Cell Carcinoma

description: A non-small cell carcinoma of the lung that has spread from its original site of growth to nearby tissues or lymph nodes.


name: Stage 0 Non-Small Cell Lung Cancer AJCC v6 and v7

description: Stage 0 includes: Tis, N0, M0.  Tis: Carcinoma in situ.  N0: No regional lymph node metastasis.  M0: No distant metastasis. (AJCC 6th and 7th eds.)


Occult Lung Cancer AJCC v8

description: Occult lung cancer includes: TX, N0, M0. TX: Primary tumor cannot be assessed. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)


Resectable Lung Adenocarcinoma

description: Lung adenocarcinoma that is amenable to surgical resection.


Advanced Lung Neuroendocrine Carcinoma

description: Lung neuroendocrine carcinoma that has spread extensively to other anatomic sites or is no longer responding to treatment.


Refractory Lung Squamous Cell Carcinoma

description: Lung squamous cell carcinoma that is resistant to treatment.


Childhood Lung Small Cell Carcinoma

description: A rare small cell carcinoma of the lung that occurs during childhood.


name: Invasive Lung Non-Mucinous Adenocarcinoma

description: An invasive adenocarcinoma that arises from the lung. It is characterized by the absence of tall columnar cells and mucin production. This category includes lepidic adenocarcinoma, acinar adenocarcinoma, papillary adenocarcinoma, micropapillary adenocarcinoma, and solid adenocarcinoma.


Lung Small Cell Carcinoma, A Subtype

description: A molecular subtype of lung small cell carcinoma characterized by the overexpression of achaete-scute homolog 1 (ASCL1) transcription factor. It is associated with high expression of neuroendocrine markers and classic morphology.


name: Refractory Lung Non-Small Cell Squamous Carcinoma

description: Lung non-small cell squamous carcinoma that is resistant to treatment.


Lung Carcinoma Metastatic in the Brain

description: A carcinoma that has spread to the brain from its original site in the lung, through the hematogenous route.


Stage IIIC Lung Cancer AJCC v8

description: Stage IIIC includes: (T3, N3, M0); (T4, N3, M0). T3: Tumor measuring more than 5 cm but 7 cm or less in greatest dimension or directly invading any of the following: parietal pleura (PL3), chest wall (including superior sulcus tumors), phrenic nerve, parietal pericardium; or separate tumor nodule(s) in the same lobe as the primary. T4: Tumor measuring more than 7 cm or tumor of any size invading one or more of the following: diaphragm, mediastinum, heart, great vessels, trachea, recurrent laryngeal nerve, esophagus, vertebral body, or carina; separate tumor nodule(s) in an ipsilateral lobe different from that of the primary. N3: Metastasis in contralateral mediastinal, contralateral hilar, ipsilateral or contralateral scalene, or supraclavicular lymph node(s). M0: No distant metastasis. (AJCC 8th ed.)


Advanced Lung Neuroendocrine Neoplasm

description: A lung neuroendocrine neoplasm that has spread extensively to other anatomic sites or is no longer responding to treatment.


Metastatic Lung Small Cell Carcinoma

description: A small cell carcinoma that arises from the lung and has metastasized to another anatomic site.


name: Refractory Extensive Stage Lung Small Cell Carcinoma

description: Extensive stage small cell lung carcinoma that does not respond to treatment.


name: Stage 0 Squamous Cell Lung Carcinoma AJCC v6 and v7


name: Unresectable Lung Non-Small Cell Squamous Carcinoma

description: Lung non-small cell squamous carcinoma that is not amenable to surgical resection.


Non-small cell lung cancer stage III

description: Stage III includes: IIIA (T1a, N2, M0); (T1b, N2, M0); (T2a, N2, M0); (T2b, N2, M0); (T3, N1, M0); (T3, N2, M0); (T4, N0, M0); (T4, N1, M0) and IIIB (T1a, N3, M0); (T1b, N3, M0); (T2a, N3, M0); (T2b, N3, M0); (T3, N3, M0); (T4, N2, M0); (T4, N3, M0).  T4: Lung cancer with a tumor of any size that invades any of the following: mediastinum, heart, great vessels, trachea, recurrent laryngeal nerve, esophagus, vertebral body, carina, and separate tumor nodule(s) in a different ipsilateral lobe.  N1: Lung cancer with metastasis in ipsilateral peribronchial and/or ipsilateral hilar lymph nodes and intrapulmonary lymph nodes, including involvement by direct extension.  N2: Lung cancer with metastasis to ipsilateral mediastinal and/or subcarinal lymph nodes.  N3: Lung cancer with metastasis to contralateral mediastinal, contralateral hilar, ipsilateral or contralateral scalene, or supraclavicular lymph nodes.  M0: No distant metastasis. (AJCC 7th ed.)


Occult Lung Carcinoma

description: A lung carcinoma detectable by sputum cytology or bronchial washings only.  The primary tumor is undetectable radiographically or during bronchoscopy; therefore, it can not be assessed.


name: Platinum-Resistant Lung Small Cell Carcinoma

description: Lung small cell carcinoma that is resistant to platinum therapy.


name: Lung Squamous Cell Carcinoma, Small Cell Variant

description: A poorly differentiated morphologic variant of squamous cell lung carcinoma characterized by the presence of small tumor cells with focal squamous differentiation.


Lung squamous cell carcinoma metastatic

description: A squamous cell carcinoma that arises from the lung and has metastasized to another anatomic site.


name: Lung Non-Keratinizing Squamous Cell Carcinoma

description: A squamous cell lung carcinoma characterized by the absence of keratinization, pearl formation, and intercellular bridges.


Stage IIIB Lung Cancer AJCC v8

description: Stage IIIB includes: (T1a, N3, M0); (T1b, N3, M0); (T1c, N3, M0); (T2a, N3, M0); (T2b, N3, M0); (T3, N2, M0); (T4, N2, M0). T1a: Tumor measuring 1 cm or less in greatest dimension. A superficial, spreading tumor of any size whose invasive component is limited to the bronchial wall and may extend proximal to the main bronchus also is classified as T1a, but these tumors are uncommon. T1b: Tumor measuring more than 1 cm but 2 cm or less in greatest dimension. T1c: Tumor measuring more than 2 cm but 3 cm or less in greatest dimension. T2a: Tumor measuring more than 3 cm but 4 cm or less in greatest dimension. T2b: Tumor measuring more than 4 cm but 5 cm or less in greatest dimension. T3: Tumor measuring more than 5 cm but 7 cm or less in greatest dimension or directly invading any of the following: parietal pleura (PL3), chest wall (including superior sulcus tumors), phrenic nerve, parietal pericardium; or separate tumor nodule(s) in the same lobe as the primary. T4: Tumor measuring more than 7 cm or tumor of any size invading one or more of the following: diaphragm, mediastinum, heart, great vessels, trachea, recurrent laryngeal nerve, esophagus, vertebral body, or carina; separate tumor nodule(s) in an ipsilateral lobe different from that of the primary. N2: Metastasis in ipsilateral mediastinal and/or subcarinal lymph node(s). N3: Metastasis in contralateral mediastinal, contralateral hilar, ipsilateral or contralateral scalene, or supraclavicular lymph node(s). M0: No distant metastasis. (AJCC 8th ed.)


name: Stage IA Lung Squamous Cell Carcinoma AJCC v7

description: Stage IA includes: (T1a, N0, M0); (T1b, N0, M0).  T1a: Lung cancer with a tumor size of 2 cm or less in greatest dimension, surrounded by lung or visceral pleura and without bronchoscopic evidence of invasion more proximal than the lobar bronchus (i.e., not in the main bronchus). The uncommon superficial tumor of any size with its invasive component limited to the bronchial wall, which may extend proximal to the main bronchus, is also classified as T1a.  T1b: Lung cancer with a tumor size more than 2 cm but 3 cm or less in greatest dimension, surrounded by lung or visceral pleura and without bronchoscopic evidence of invasion more proximal than the lobar bronchus (i.e., not in the main bronchus).  N0: No regional lymph metastasis.  M0: No distant metastasis. (AJCC 7th ed.)


Solid Lung Adenocarcinoma

description: A morphologic variant of lung adenocarcinoma characterized by the presence of polygonal malignant cells forming sheets. Acinar, papillary, micropapillary, or lepidic growth patterns are absent.  If the tumor is 100 percent solid, intracellular mucin should be present in at least five tumor cells in each of two high-power fields and confirmed with mucin immunohistochemical stains. Tumors formerly classified as large cell carcinomas expressing pneumocyte immunohistochemical markers, even if intracellular mucin is absent, are now included in this category.


description: A morphologic variant of minimally invasive lung  adenocarcinoma characterized by the presence of Clara cells and/or type II cells.


rhabdomyosarcoma of lung

description: A rare rhabdomyosarcoma that arises from the lung.


name: Locally Advanced Lung Large Cell Neuroendocrine Carcinoma

description: Lung large cell neuroendocrine carcinoma that has spread from its original site of growth to nearby tissues or lymph nodes.


name: Stage IIB Non-Small Cell Lung Carcinoma AJCC v7

description: Stage IIB includes: (T2b, N1, M0); (T3, N0, M0).  T2b: Lung cancer with a tumor size more than 5 cm but 7 cm or less in greatest dimension.  T3: Lung cancer with a tumor size more than 7 cm or one that directly invades any of the following: parietal pleural (PL3) chest wall (including superior sulcus tumors), diaphragm, phrenic nerve, mediastinal pleura, parietal pericardium; or tumor in the main bronchus (less than 2 cm distal to the carina but without involvement of the carina); or associated atelectasis or obstructive pneumonitis of the entire lung or separate tumor nodule(s) in the same lobe. N0: No regional lymph node metastasis.  N1: Lung cancer with metastasis in ipsilateral peribronchial and/or ipsilateral hilar lymph nodes and intrapulmonary lymph nodes, including involvement by direct extension. M0: No distant metastasis. (AJCC 7th ed.)


Lung Cancer by AJCC v7 Stage

description: A term that refers to the staging of lung carcinoma according to the American Joint Committee on Cancer, 7th edition.


name: Unresectable Lung Non-Small Cell Carcinoma

description: Lung non-small cell carcinoma that is not amenable to surgical resection.


Stage IIIA Lung Cancer AJCC v8

description: Stage IIIA includes: (T1a, N2, M0); (T1b, N2, M0); (T1c, N2, M0); (T2a, N2, M0); (T2b, N2, M0); (T3, N1, M0); (T4, N0, M0); (T4, N1, M0). T1a: Tumor measuring 1 cm or less in greatest dimension. A superficial, spreading tumor of any size whose invasive component is limited to the bronchial wall and may extend proximal to the main bronchus also is classified as T1a, but these tumors are uncommon. T1b: Tumor measuring more than 1 cm but 2 cm or less in greatest dimension. T1c: Tumor measuring more than 2 cm but 3 cm or less in greatest dimension. T2a: Tumor measuring more than 3 cm but 4 cm or less in greatest dimension. T2b: Tumor measuring more than 4 cm but 5 cm or less in greatest dimension. T3: Tumor measuring more than 5 cm but 7 cm or less in greatest dimension or directly invading any of the following: parietal pleura (PL3), chest wall (including superior sulcus tumors), phrenic nerve, parietal pericardium; or separate tumor nodule(s) in the same lobe as the primary. T4: Tumor measuring more than 7 cm or tumor of any size invading one or more of the following: diaphragm, mediastinum, heart, great vessels, trachea, recurrent laryngeal nerve, esophagus, vertebral body, or carina; separate tumor nodule(s) in an ipsilateral lobe different from that of the primary. N0: No regional lymph node metastases. N1: Metastasis in ipsilateral peribronchial and/or ipsilateral hilar lymph nodes and intrapulmonary nodes, including involvement by direct extension. N2: Metastasis in ipsilateral mediastinal and/or subcarinal lymph node(s). M0: No distant metastasis. (AJCC 8th ed.)


Myoepithelial carcinoma of lung

description: A very rare malignant lung tumor with myoepithelial differentiation.


Unresectable Lung Carcinoid Tumor

description: Lung neuroendocrine tumor that is not amenable to surgical resection.


name: Resectable Lung Non-Small Cell Carcinoma

description: Lung non-small cell carcinoma that is amenable to surgical resection.


Occult Lung Adenosquamous Carcinoma

description: An adenosquamous lung carcinoma detectable by sputum cytology only.  The primary tumor is undetectable radiographically or during bronchoscopy; therefore, it can not be assessed.


Metastatic Lung Neuroendocrine Neoplasm

description: A neuroendocrine neoplasm that arises from the lung and has spread to another anatomic site.


name: Stage IIIB Lung Small Cell Carcinoma without Pleural Effusion AJCC v7

description: Stage IIIB small cell lung carcinoma that has not spread to the pleural fluid.


name: Epithelioid hemangioendothelioma of lung

description: A low-grade malignant blood vessel neoplasm arising from the lung.  It is characterized by the presence of epithelioid endothelial cells.  The neoplastic cells are arranged in cords and nests, which are embedded in a myxoid to hyalinized stroma.


name: Metastatic Lung Large Cell Neuroendocrine Carcinoma

description: Lung large cell neuroendocrine carcinoma that has spread from its original site of growth to another anatomic site.


name: Lung Non-Small Cell Cancer by AJCC v7 Stage

description: A term that refers to the staging of non-small cell lung carcinoma, following the rules of the TNM AJCC v7 classification system.


Stage IIIA Lung Cancer AJCC v7

description: Stage IIIA includes: (T1a, N2, M0); (T1b, N2, M0); (T2a, N2, M0); (T2b, N2, M0); (T3, N1, M0); (T3, N2, M0); (T4, N0, M0); (T4, N1, M0).  T4: Lung cancer with a tumor of any size that invades any of the following: mediastinum, heart, great vessels, trachea, recurrent laryngeal nerve, esophagus, vertebral body, carina, and separate tumor nodule(s) in a different ipsilateral lobe.  N1: Lung cancer with metastasis in ipsilateral peribronchial and/or ipsilateral hilar lymph nodes and intrapulmonary lymph nodes, including involvement by direct extension.  N2: Lung cancer with metastasis to ipsilateral mediastinal and/or subcarinal lymph nodes.  M0: No distant metastasis. (AJCC 7th ed.)


name: Metastatic Lung Neuroendocrine Carcinoma

description: Lung neuroendocrine carcinoma that has spread from its original site of growth to another anatomic site.


Advanced Lung Non-Small Cell Carcinoma

description: Lung non-small cell carcinoma that has spread extensively to other anatomic sites or is no longer responding to treatment.


Resectable Lung Squamous Cell Carcinoma

description: Lung squamous cell carcinoma that is amenable to surgical resection.


Metastatic Lung Carcinoma

description: A carcinoma that arises from the lung and has metastasized to another anatomic site.


name: Advanced Lung Non-Small Cell Squamous Carcinoma

description: Non-small cell squamous lung carcinoma that has spread extensively to other anatomic sites or is no longer responding to treatment.


name: Stage IIIA Lung Small Cell Carcinoma AJCC v7


Lung Osteosarcoma

description: A rare extraskeletal osteosarcoma that arises from the lung parenchyma.


Lung Alveolar Soft Part Sarcoma

description: An exceptionally rare alveolar soft part sarcoma that arises from the lung.


Unresectable Lung Adenocarcinoma

description: Lung adenocarcinoma that is not amenable to surgical resection.


name: Stage 0 Lung Adenocarcinoma AJCC v6 and v7

description: Stage 0 includes: Tis, N0, M0.  Tis: Carcinoma in situ.  N0: No regional lymph node metastasis.  M0: No distant metastasis. (AJCC 6th and 7th eds.)


Stage IB Lung Adenocarcinoma AJCC v7

description: Stage IB includes: T2a, N0, M0.  T2a: Lung cancer with a tumor size more than 3 cm but 5 cm or less in greatest dimension.  N0: No regional lymph metastasis.  M0: No distant metastasis. (AJCC 7th ed.)


name: Locally Advanced Lung Adenosquamous Carcinoma

description: Lung adenosquamous carcinoma that has spread from its original site of growth to nearby tissues or lymph nodes.


Stage IA1 Lung Cancer AJCC v8

description: Stage IA1 includes: IA1: (T1mi, N0, M0); (T1a, N0, M0). T1mi: Minimally invasive adenocarcinoma: adenocarcinoma (3 cm or less in greatest dimension) with a predominantly lepidic pattern and 5 mm or less invasion in greatest dimension. T1a: Tumor measuring 1 cm or less in greatest dimension. A superficial, spreading tumor of any size whose invasive component is limited to the bronchial wall and may extend proximal to the main bronchus also is classified as T1a, but these tumors are uncommon. N0: No regional lymph node metastases. M0: No distant metastasis. (AJCC 8th ed.)


name: Stage IB Lung Squamous Cell Carcinoma AJCC v7


Lung Small Cell Carcinoma, N Subtype

description: A molecular subtype of lung small cell carcinoma characterized by the overexpression of neurogenic differentiation factor 1 (NEUROD1). It is associated with low expression of neuroendocrine markers and variant morphology.


Stage IVA Lung Cancer AJCC v8

description: Stage IVA includes: (Any T, Any N, M1a); (Any T, Any N, M1b). M1a: Tumor with separate tumor nodule(s) in a contralateral lobe; tumor with pleural or pericardial nodules or malignant pleural or pericardial effusion. Most pleural (pericardial) effusions with lung cancer are a result of the tumor. In a few patients, however, multiple microscopic examinations of pleural (pericardial) fluid are negative for tumor, and the fluid is nonbloody and not an exudate. If these elements and clinical judgment dictate that the effusion is not related to the tumor, the effusion should be excluded as a staging descriptor. M1b: Tumor with single extrathoracic metastasis in a single organ (including involvement of a single nonregional node). (AJCC 8th ed.)


name: Advanced Lung Large Cell Neuroendocrine Carcinoma

description: Lung large cell neuroendocrine carcinoma that has spread extensively to other anatomic sites or is no longer responding to treatment.


Childhood Malignant Lung Neoplasm

description: A malignant neoplasm that involves the lungs during childhood.


name: Stage II Lung Small Cell Carcinoma AJCC v7

description: Stage II includes: IIA (T2b, N0, M0); (T1a, N1, M0); (T1b, N1, M0); (T2a, N1, M0) and IIB (T2b, N1, M0); (T3, N0, M0).  T2b: Lung cancer with a tumor size more than 5 cm but 7 cm or less in greatest dimension.  T1a: Lung cancer with a tumor size of 2 cm or less in greatest dimension, surrounded by lung or visceral pleura and without bronchoscopic evidence of invasion more proximal than the lobar bronchus (i.e., not in the main bronchus). The uncommon superficial tumor of any size with its invasive component limited to the bronchial wall, which may extend proximal to the main bronchus, is also classified as T1a.  T1b: Lung cancer with a tumor size more than 2 cm but 3 cm or less in greatest dimension, surrounded by lung or visceral pleura and without bronchoscopic evidence of invasion more proximal than the lobar bronchus (i.e., not in the main bronchus).  T2a: Lung cancer with a tumor size more than 3 cm but 5 cm or less in greatest dimension.  T3: Lung cancer with a tumor size more than 7 cm or one that directly invades any of the following: parietal pleural (PL3) chest wall (including superior sulcus tumors), diaphragm, phrenic nerve, mediastinal pleura, parietal pericardium; or tumor in the main bronchus (less than 2 cm distal to the carina but without involvement of the carina); or associated atelectasis or obstructive pneumonitis of the entire lung or separate tumor nodule(s) in the same lobe. N0: No regional lymph node metastasis.  N1: Lung cancer with metastasis in ipsilateral peribronchial and/or ipsilateral hilar lymph nodes and intrapulmonary lymph nodes, including involvement by direct extension. M0: No distant metastasis. (AJCC 7th ed.)


Stage III Lung Cancer AJCC v7

description: Stage III includes: IIIA (T1a, N2, M0); (T1b, N2, M0); (T2a, N2, M0); (T2b, N2, M0); (T3, N1, M0); (T3, N2, M0); (T4, N0, M0); (T4, N1, M0) and IIIB (T1a, N3, M0); (T1b, N3, M0); (T2a, N3, M0); (T2b, N3, M0); (T3, N3, M0); (T4, N2, M0); (T4, N3, M0).  T4: Lung cancer with a tumor of any size that invades any of the following: mediastinum, heart, great vessels, trachea, recurrent laryngeal nerve, esophagus, vertebral body, carina, and separate tumor nodule(s) in a different ipsilateral lobe.  N1: Lung cancer with metastasis in ipsilateral peribronchial and/or ipsilateral hilar lymph nodes and intrapulmonary lymph nodes, including involvement by direct extension.  N2: Lung cancer with metastasis to ipsilateral mediastinal and/or subcarinal lymph nodes.  N3: Lung cancer with metastasis to contralateral mediastinal, contralateral hilar, ipsilateral or contralateral scalene, or supraclavicular lymph nodes.  M0: No distant metastasis. (AJCC 7th ed.)


Stage I Lung Cancer AJCC v7

description: Stage I includes: IA: (T1a, N0, M0); (T1b, N0, M0) and IB: (T2a, N0, M0).  T1a: Lung cancer with a tumor size of 2 cm or less n greatest dimension, surrounded by lung or visceral pleura and without bronchoscopic evidence of invasion more proximal than the lobar bronchus (i.e., not in the main bronchus). The uncommon superficial tumor of any size with its invasive component limited to the bronchial wall, which may extend proximal to the main bronchus, is also classified as T1a.  T1b: Lung cancer with a tumor size more than 2 cm but 3 cm or less in greatest dimension, surrounded by lung or visceral pleura and without bronchoscopic evidence of invasion more proximal than the lobar bronchus (i.e., not in the main bronchus).  T2a: Lung cancer with a tumor size more than 3 cm but 5 cm or less in greatest dimension.  N0: No regional lymph metastasis.  M0: No distant metastasis. (AJCC 7th ed.)


Lung Plasmacytoma

description: A plasmacytoma that arises in the lung.


Adenocarcinoma of lung stage IIIA

description: Stage IIIA includes: (T1a, N2, M0); (T1b, N2, M0); (T2a, N2, M0); (T2b, N2, M0); (T3, N1, M0); (T3, N2, M0); (T4, N0, M0); (T4, N1, M0).  T4: Lung cancer with a tumor of any size that invades any of the following: mediastinum, heart, great vessels, trachea, recurrent laryngeal nerve, esophagus, vertebral body, carina, and separate tumor nodule(s) in a different ipsilateral lobe.  N1: Lung cancer with metastasis in ipsilateral peribronchial and/or ipsilateral hilar lymph nodes and intrapulmonary lymph nodes, including involvement by direct extension.  N2: Lung cancer with metastasis to ipsilateral mediastinal and/or subcarinal lymph nodes.  M0: No distant metastasis. (AJCC 7th ed.)


Stage IIB Lung Cancer AJCC v7

description: Stage IIB includes: (T2b, N1, M0); (T3, N0, M0).  T2b: Lung cancer with a tumor size more than 5 cm but 7 cm or less in greatest dimension.  T3: Lung cancer with a tumor size more than 7 cm or one that directly invades any of the following: parietal pleural (PL3) chest wall (including superior sulcus tumors), diaphragm, phrenic nerve, mediastinal pleura, parietal pericardium; or tumor in the main bronchus (less than 2 cm distal to the carina but without involvement of the carina); or associated atelectasis or obstructive pneumonitis of the entire lung or separate tumor nodule(s) in the same lobe. N0: No regional lymph node metastasis.  N1: Lung cancer with metastasis in ipsilateral peribronchial and/or ipsilateral hilar lymph nodes and intrapulmonary lymph nodes, including involvement by direct extension. M0: No distant metastasis. (AJCC 7th ed.)


name: Stage IB Non-Small Cell Lung Carcinoma AJCC v7


Metastatic Lung Adenosquamous Carcinoma

description: An adenosquamous carcinoma that arises from the lung and has metastasized to another anatomic site.


Hodgkin's lymphoma of lung

description: A rare Hodgkin lymphoma that arises in and is confined to the lung at the time of diagnosis.


EGFR-Positive Lung Adenocarcinoma

description: Lung adenocarcinoma that is associated with EGFR gene mutation.


name: Stage IB Lung Small Cell Carcinoma AJCC v7


Localized Lung Carcinoma

description: Lung carcinoma that is confined to the site in which it initially manifested without evidence of spread to other anatomic sites.


Refractory Lung Small Cell Carcinoma

description: Small cell lung carcinoma that does not respond to treatment.


Stage I Lung Cancer AJCC v6

description: Stage I includes: IA: (TI, N0, M0) and IB: (T2, N0, M0).  TI: Tumor 3 cm or less in greatest dimension surrounded by lung or visceral pleura, without bronchoscopic evidence of invasion more proximal than the lobar bronchus.  T2: Tumor with any of the following features of size or extent: More than 3cm in greatest dimension.  Involves main bronchus, 2cm or more distal to the carina.  Invades the visceral pleura.  N0: No regional lymph metastasis.  M0: No distant metastasis. (AJCC 6th ed.)


name: Locally Advanced Lung Neuroendocrine Carcinoma

description: Lung neuroendocrine carcinoma that has spread from its original site of growth to nearby tissues or lymph nodes.


Stage IA3 Lung Cancer AJCC v8

description: Stage IA3 includes: T1c, N0, M0. T1c: Tumor measuring more than 2 cm but 3 cm or less in greatest dimension. N0: No regional lymph node metastases. M0: No distant metastasis. (AJCC 8th ed.)


name: Lung Small Cell Carcinoma Molecular Subtypes

description: A header term that refers to the molecular classification of lung small cell carcinoma according to the relative expression of four transcription factors: achaete-scute homolog 1 (ASCL1), neurogenic differentiation factor 1 (NEUROD1), yes-associated protein 1 (YAP1), and POU class 2 homeobox 3 (POU2F3).


Stage II Lung Cancer AJCC v8

description: Stage II includes: IIA: (T2b, N0, M0); IIB: (T1a, N1, M0); (T1b, N1, M0); (T1c, N1, M0); (T2a, N1, M0); (T2b, N1, M0); (T3, N0, M0). T2b: Tumor measuring more than 4 cm but 5 cm or less in greatest dimension.  T1a: Tumor measuring 1 cm or less in greatest dimension. A superficial, spreading tumor of any size whose invasive component is limited to the bronchial wall and may extend proximal to the main bronchus also is classified as T1a, but these tumors are uncommon. T1b: Tumor measuring more than 1 cm but 2 cm or less in greatest dimension. T1c: Tumor measuring more than 2 cm but 3 cm or less in greatest dimension.  T2a: Tumor measuring more than 3 cm but 4 cm or less in greatest dimension. T3: Tumor measuring more than 5 cm but 7 cm or less in greatest dimension or directly invading any of the following: parietal pleura (PL3), chest wall (including superior sulcus tumors), phrenic nerve, parietal pericardium; or separate tumor nodule(s) in the same lobe as the primary. N0: No regional lymph node metastases. N1: Metastasis in ipsilateral peribronchial and/or ipsilateral hilar lymph nodes and intrapulmonary nodes, including involvement by direct extension. M0: No distant metastasis. (AJCC 8th ed.)


Unresectable Lung Carcinoma

description: Lung carcinoma that is not amenable to surgical resection.


Lung Hyalinizing Clear Cell Carcinoma

description: An extremely rare, low-grade carcinoma that arises endobronchially in the central airways. It is composed of small to medium-sized malignant epithelial cells with clear and eosinophilic cytoplasm forming nests, cords, and trabeculae in a hyalinized stroma. It is associated with the presence of EWSR1-ATF1 fusion gene.


name: Stage IA Lung Non-Small Cell Carcinoma AJCC v7

description: Stage IA includes: (T1a, N0, M0); (T1b, N0, M0).  T1a: Lung cancer with a tumor size of 2 cm or less in greatest dimension, surrounded by lung or visceral pleura and without bronchoscopic evidence of invasion more proximal than the lobar bronchus (i.e., not in the main bronchus). The uncommon superficial tumor of any size with its invasive component limited to the bronchial wall, which may extend proximal to the main bronchus, is also classified as T1a.  T1b: Lung cancer with a tumor size more than 2 cm but 3 cm or less in greatest dimension, surrounded by lung or visceral pleura and without bronchoscopic evidence of invasion more proximal than the lobar bronchus (i.e., not in the main bronchus).  N0: No regional lymph metastasis.  M0: No distant metastasis. (AJCC 7th ed.)


Stage III Lung Cancer AJCC v6

description: Stage III includes: IIIA (T1, N2, M0); (T2, N2, M0); (T3, N1,M0); (T3, N2, M0) or IIIB (Any T, N3, M0); (T4, Any N, M0).  N1: Metastasis to ipsilateral peribronchial and/or ipsilateral hilar lymph nodes, and intrapulmonary nodes including involvement by direct extension of the primary tumor.  N2: Metastasis to ipsilateral mediastinal and/or subcarinal lymph node(s).  N3: Metastasis to contralateral mediastinal, contralateral hilar, ipsilateral or contralateral scalene, or supraclavicular lymph node(s).  T1: Tumor is 3 cm or less in greatest dimension, surrounded by lung or visceral pleura, and without bronchoscopic evidence of invasion more proximal than the lobar bronchus.  T2: Tumor has any of the following features of size or extent: more than 3 cm in greatest dimension; involves the main bronchus, 2 cm or more distal to the carina; invades the visceral pleura; associated with atelectasis or obstructive pneumonitis that extends to the hilar region but does not involve the entire lung.  T3: Tumor (of any size) directly invades any of the following: chest wall (including superior sulcus tumors), diaphragm, mediastinal pleura, parietal pericardium; or tumor in the main bronchus less than 2 cm distal to the carina but without involvement of the carina; or associated atelectasis or obstructive pneumonitis of the entire lung.  T4: Tumor of any size that invades any of the following: mediastinum, heart, great vessels, trachea, esophagus, vertebral body, carina; or separate tumor nodules in the same lobe; or tumor with a malignant pleural effusion.  M0: No distant metastasis. (AJCC 6th ed.)


Refractory Lung Carcinoma

description: Lung carcinoma that does not respond to treatment.


Metastatic Carcinoma in the Lung

description: The spread of a carcinoma to the lung. This may be from a primary lung carcinoma, or from a carcinoma at a distant anatomic site.


Non-small cell lung cancer stage IIIA

description: Stage IIIA includes: (T1a, N2, M0); (T1b, N2, M0); (T2a, N2, M0); (T2b, N2, M0); (T3, N1, M0); (T3, N2, M0); (T4, N0, M0); (T4, N1, M0).  T4: Lung cancer with a tumor of any size that invades any of the following: mediastinum, heart, great vessels, trachea, recurrent laryngeal nerve, esophagus, vertebral body, carina, and separate tumor nodule(s) in a different ipsilateral lobe.  N1: Lung cancer with metastasis in ipsilateral peribronchial and/or ipsilateral hilar lymph nodes and intrapulmonary lymph nodes, including involvement by direct extension.  N2: Lung cancer with metastasis to ipsilateral mediastinal and/or subcarinal lymph nodes.  M0: No distant metastasis. (AJCC 7th ed.)


Transplant-Related Lung Carcinoma

description: A lung carcinoma that arises in a patient with a history of organ transplantation.


Lung Cancer by AJCC v8 Stage

description: A term that refers to the staging of lung cancer, following the rules of the TNM AJCC v8 classification system. This staging system derives from analyses of the new retrospective and prospective databases of the International Association for the Study of Lung Cancer (IASLC). These databases contain information on patients diagnosed with lung cancer from 1999 to 2010 originating from 35 different databases in 16 countries around the world. This staging system applies to carcinomas of the lung, including non-small cell and small cell carcinomas, and bronchopulmonary carcinoid tumors. It does not apply to sarcomas or other rare tumors of the lung. (from AJCC 8th Ed.)


Lung Malignant PEComa

description: A malignant lung tumor that arises from perivascular epithelioid cells (PECs).


Adenocarcinoma of lung, stage III

description: Stage III includes: IIIA (T1a, N2, M0); (T1b, N2, M0); (T2a, N2, M0); (T2b, N2, M0); (T3, N1, M0); (T3, N2, M0); (T4, N0, M0); (T4, N1, M0) and IIIB (T1a, N3, M0); (T1b, N3, M0); (T2a, N3, M0); (T2b, N3, M0); (T3, N3, M0); (T4, N2, M0); (T4, N3, M0).  T4: Lung cancer with a tumor of any size that invades any of the following: mediastinum, heart, great vessels, trachea, recurrent laryngeal nerve, esophagus, vertebral body, carina, and separate tumor nodule(s) in a different ipsilateral lobe.  N1: Lung cancer with metastasis in ipsilateral peribronchial and/or ipsilateral hilar lymph nodes and intrapulmonary lymph nodes, including involvement by direct extension.  N2: Lung cancer with metastasis to ipsilateral mediastinal and/or subcarinal lymph nodes.  N3: Lung cancer with metastasis to contralateral mediastinal, contralateral hilar, ipsilateral or contralateral scalene, or supraclavicular lymph nodes.  M0: No distant metastasis. (AJCC 7th ed.)


name: Lung Small Cell Carcinoma, Neuroendocrine-High Subtype

description: Lung small cell carcinoma characterized by high expression pattern of different neuroendocrine markers such as chromogranin A, synaptophysin, neural cell adhesion molecule 1, and gastrin-releasing peptide. It is associated with low numbers of infiltrating immune cells (immune desert phenotype).


Stage IIB Lung Cancer AJCC v8

description: Stage IIB includes: (T1a, N1, M0); (T1b, N1, M0); (T1c, N1, M0); (T2a, N1, M0); (T2b, N1, M0); (T3, N0, M0). T1a: Tumor measuring 1 cm or less in greatest dimension. A superficial, spreading tumor of any size whose invasive component is limited to the bronchial wall and may extend proximal to the main bronchus also is classified as T1a, but these tumors are uncommon. T1b: Tumor measuring more than 1 cm but 2 cm or less in greatest dimension. T1c: Tumor measuring more than 2 cm but 3 cm or less in greatest dimension. T2a: Tumor measuring more than 3 cm but 4 cm or less in greatest dimension. T2b: Tumor measuring more than 4 cm but 5 cm or less in greatest dimension. T3: Tumor measuring more than 5 cm but 7 cm or less in greatest dimension or directly invading any of the following: parietal pleura (PL3), chest wall (including superior sulcus tumors), phrenic nerve, parietal pericardium; or separate tumor nodule(s) in the same lobe as the primary. N0: No regional lymph node metastases. N1: Metastasis in ipsilateral peribronchial and/or ipsilateral hilar lymph nodes and intrapulmonary nodes, including involvement by direct extension. M0: No distant metastasis. (AJCC 8th ed.)


name: Lung Small Cell Carcinoma by AJCC v7 Stage

description: A term that refers to the staging of small cell lung carcinoma, following the rules of the TNM AJCC v7 classification system.


Lung Biphasic Synovial Sarcoma

description: A biphasic synovial sarcoma arising from the lungs.


thoracic cancer

description: A primary or metastatic malignant neoplasm affecting the tissues of the thorax.


name: Advanced Lung Non-Squamous Non-Small Cell Carcinoma

description: Non-squamous non-small cell lung carcinoma that has spread extensively to other anatomic sites or is no longer responding to treatment.


name: Locally Advanced Lung Non-Squamous Non-Small Cell Carcinoma

description: Non-squamous non-small cell lung carcinoma that has spread from its original site of growth to nearby tissues or lymph nodes.


Colon Carcinoma Metastatic in the Lung

description: A carcinoma that originates from the colonic wall and has spread to the lungs.


Adenocarcinoma of lung, stage II

description: Stage II includes: IIA (T2b, N0, M0); (T1a, N1, M0); (T1b, N1, M0); (T2a, N1, M0) and IIB (T2b, N1, M0); (T3, N0, M0).  T2b: Lung cancer with a tumor size more than 5 cm but 7 cm or less in greatest dimension.  T1a: Lung cancer with a tumor size of 2 cm or less in greatest dimension, surrounded by lung or visceral pleura and without bronchoscopic evidence of invasion more proximal than the lobar bronchus (i.e., not in the main bronchus). The uncommon superficial tumor of any size with its invasive component limited to the bronchial wall, which may extend proximal to the main bronchus, is also classified as T1a.  T1b: Lung cancer with a tumor size more than 2 cm but 3 cm or less in greatest dimension, surrounded by lung or visceral pleura and without bronchoscopic evidence of invasion more proximal than the lobar bronchus (i.e., not in the main bronchus).  T2a: Lung cancer with a tumor size more than 3 cm but 5 cm or less in greatest dimension.  T3: Lung cancer with a tumor size more than 7 cm or one that directly invades any of the following: parietal pleural (PL3) chest wall (including superior sulcus tumors), diaphragm, phrenic nerve, mediastinal pleura, parietal pericardium; or tumor in the main bronchus (less than 2 cm distal to the carina but without involvement of the carina); or associated atelectasis or obstructive pneumonitis of the entire lung or separate tumor nodule(s) in the same lobe. N0: No regional lymph node metastasis.  N1: Lung cancer with metastasis in ipsilateral peribronchial and/or ipsilateral hilar lymph nodes and intrapulmonary lymph nodes, including involvement by direct extension. M0: No distant metastasis. (AJCC 7th ed.)


Advanced Lung Carcinoma

description: A lung carcinoma that has spread extensively to other anatomic sites or is no longer responding to treatment.


name: Stage III Lung Small Cell Carcinoma AJCC v7


Stage IV Lung Cancer AJCC v6

description: Stage IV includes: Any T, Any N, M1.  M1: Distant metastasis present. (AJCC 6th ed.)


Lung Squamous Cell Carcinoma In Situ

description: A preinvasive bronchial neoplastic lesion affecting the squamous epithelium. It is characterized by the absence of progression of maturation from base to luminal surface, basilar zone expansion with cellular crowding throughout the epithelium, absence of the intermediate zone, and surface flattening confined to the most superficial cells. The nuclear-to-cytoplasmic ratio is often high and variable, the chromatin is coarse and uneven, and mitotic figures are present through full thickness. The cell size may be markedly increased. Anisocytosis and pleomorphism may be present. (Adapted from WHO, 2015)


Stage IIA Lung Adenocarcinoma AJCC v7

description: Stage IIA includes: (T2b, N0, M0); (T1a, N1, M0); (T1b, N1, M0); (T2a, N1, M0).  T2b: Lung cancer with a tumor size more than 5 cm but 7 cm or less in greatest dimension.  T1a: Lung cancer with a tumor size of 2 cm or less in greatest dimension, surrounded by lung or visceral pleura and without bronchoscopic evidence of invasion more proximal than the lobar bronchus (i.e., not in the main bronchus). The uncommon superficial tumor of any size with its invasive component limited to the bronchial wall, which may extend proximal to the main bronchus, is also classified as T1a.  T1b: Lung cancer with a tumor size more than 2 cm but 3 cm or less in greatest dimension, surrounded by lung or visceral pleura and without bronchoscopic evidence of invasion more proximal than the lobar bronchus (i.e., not in the main bronchus).  T2a: Lung cancer with a tumor size more than 3 cm but 5 cm or less in greatest dimension.  N0: No regional lymph node metastasis.  N1: Lung cancer with metastasis in ipsilateral peribronchial and/or ipsilateral hilar lymph nodes and intrapulmonary lymph nodes, including involvement by direct extension. M0: No distant metastasis. (AJCC 7th ed.)


name: Minimally Invasive Lung Mucinous Adenocarcinoma

description: A morphologic variant of minimally invasive lung adenocarcinoma characterized by tall columnar cells and mucin production.


Metastatic Lung Adenocarcinoma

description: Lung adenocarcinoma that has spread from its original site of growth to another anatomic site.


name: Unresectable Lung Non-Squamous Non-Small Cell Carcinoma

description: Lung non-squamous non-small cell carcinoma that is not amenable to surgical resection.


name: Unresectable Lung Large Cell Neuroendocrine Carcinoma

description: Lung large cell neuroendocrine carcinoma that is not amenable to surgical resection.


name: Locally Advanced Lung Neuroendocrine Neoplasm

description: A lung neuroendocrine neoplasm that has spread from its original site of growth to nearby tissues or lymph nodes.


name: Lung Small Cell Carcinoma Neuroendocrine Subtype

description: A header term that refers to the classification of lung small cell carcinoma based on the expression pattern of different neuroendocrine markers such as chromogranin A, synaptophysin, neural cell adhesion molecule 1, and gastrin-releasing peptide.


name: keratinizing squamous cell carcinoma of lung

description: A squamous cell lung carcinoma characterized by the presence of keratinization, pearl formation, and/or intercellular bridges.


Lung Enteric Adenocarcinoma

description: A well-differentiated adenocarcinoma located in the lung periphery. It resembles colorectal adenocarcinoma with acinar and/or cribriform architecture and papillotubular structures.


Lung Monophasic Synovial Sarcoma

description: A monophasic synovial sarcoma arising from the lungs.


name: Stage IIIB Lung Small Cell Carcinoma AJCC v7

description: Stage IIIB includes: (T1a, N3, M0); (T1b, N3, M0); (T2a, N3, M0); (T2b, N3, M0); (T3, N3, M0); (T4, N2, M0); (T4, N3, M0).  T4: Lung cancer with a tumor of any size that invades any of the following: mediastinum, heart, great vessels, trachea, recurrent laryngeal nerve, esophagus, vertebral body, carina, and separate tumor nodule(s) in a different ipsilateral lobe.  N2: Lung cancer with metastasis to ipsilateral mediastinal and/or subcarinal lymph nodes.  N3: Lung cancer with metastasis to contralateral mediastinal, contralateral hilar, ipsilateral or contralateral scalene, or supraclavicular lymph nodes.  M0: No distant metastasis. (AJCC 7th ed.)


Lung Melanoma

description: A rare malignant neoplasm that derives from melanocytes and arises from the lung in a patient with no history of previous melanoma and no evidence of melanoma in another site at the time of diagnosis.  It usually presents as a solitary lesion and the prognosis is poor.


Metastatic Lung Carcinoid Tumor

description: Lung neuroendocrine tumor that has spread from its original site of growth to another anatomic site.


Stage IV Lung Cancer AJCC v7

description: Stage IV includes: (Any T, Any N, M1a); (Any T, Any N, M1b).  M1a: Lung cancer with separate tumor nodule(s) in a contralateral lobe; tumor with pleural nodules or malignant pleural (or pericardial) effusion.  M1b: Distant metastasis. (AJCC 7th ed.)


Stage 0 Lung Cancer AJCC v8

description: Stage 0 includes: Tis, N0, M0. Tis: Carcinoma in situ. Squamous cell carcinoma in situ (SCIS). Adenocarcinoma in situ (AIS): adenocarcinoma with pure lepidic pattern, 3 cm or less in greatest dimension. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)


name: Metastatic Lung Non-Squamous Non-Small Cell Carcinoma

description: A non-squamous non-small cell carcinoma that arises from the lung and has metastasized to another anatomic site.


name: Stage IV Lung Squamous Cell Carcinoma AJCC v7


name: Stage IIA Non-Small Cell Lung Carcinoma AJCC v7


Stage IB Lung Cancer AJCC v7

description: Stage IB includes: T2a, N0, M0.  T2a: Lung cancer with a tumor size more than 3 cm but 5 cm or less in greatest dimension.  N0: No regional lymph metastasis.  M0: No distant metastasis. (AJCC 7th ed.)


Locally Advanced Lung Carcinoma

description: A lung carcinoma that has spread from its original site of growth to nearby tissues or lymph nodes.


Small cell lung cancer extensive stage

description: Small cell lung carcinoma which has spread beyond one hemi-thorax and the regional lymph nodes.


name: Lung Squamous Cell Carcinoma, Papillary Variant

description: A morphologic variant of squamous cell lung carcinoma characterized by the presence of papillary structures.


Advanced Lung Squamous Cell Carcinoma

description: Lung squamous cell carcinoma that has spread extensively to other anatomic sites or is no longer responding to treatment.


Oligometastatic Lung Carcinoma

description: Lung carcinoma that has metastasized to a limited number of sites.


name: Extramedullary Disease in Multiple Myeloma Involving the Lung

description: Infiltration of the lung by malignant (clonal) plasma cells in patients with history of multiple myeloma.


name: Stage IIB Lung Small Cell Carcinoma AJCC v7

description: Stage IIB includes: (T2b, N1, M0); (T3, N0, M0).  T2b: Lung cancer with a tumor size more than 5 cm but 7 cm or less in greatest dimension.  T3: Lung cancer with a tumor size more than 7 cm or one that directly invades any of the following: parietal pleural (PL3) chest wall (including superior sulcus tumors), diaphragm, phrenic nerve, mediastinal pleura, parietal pericardium; or tumor in the main bronchus (less than 2 cm distal to the carina but without involvement of the carina); or associated atelectasis or obstructive pneumonitis of the entire lung or separate tumor nodule(s) in the same lobe. N0: No regional lymph node metastasis.  N1: Lung cancer with metastasis in ipsilateral peribronchial and/or ipsilateral hilar lymph nodes and intrapulmonary lymph nodes, including involvement by direct extension. M0: No distant metastasis. (AJCC 7th ed.)


name: Early Stage Lung Non-Small Cell Carcinoma

description: A stage term that refers to lung non-small cell carcinoma stages I, II, and IIIA.


Lung Carcinoma Metastatic in the Liver

description: A carcinoma that originates from the lung and has spread to the liver.


name: Lung Squamous Cell Carcinoma by AJCC v7 Stage

description: A term that refers to the staging of squamous cell lung carcinoma, following the rules of the TNM AJCC v7 classification system.


name: EGFR-Positive Lung Non-Small Cell Carcinoma

description: Lung non-small cell carcinoma that is associated with EGFR gene mutation.


Advanced Lung Carcinoid Tumor

description: Lung neuroendocrine tumor that has spread extensively to other anatomic sites or is no longer responding to treatment.


name: Platinum-Sensitive Lung Small Cell Carcinoma

description: Lung small cell carcinoma that is sensitive to platinum therapy.


Lepidic Predominant Adenocarcinoma

description: A lung adenocarcinoma characterized by the presence of mildly and moderately differentiated adenocarcinoma cells across the alveolar walls with at least one focus of invasive carcinoma measuring more than 5 mm in greatest dimension.


Stage IIA Lung Cancer AJCC v8

description: Stage IIA includes: T2b, N0, M0. T2b: Tumor measuring more than 4 cm but 5 cm or less in greatest dimension.  N0: No regional lymph node metastases. M0: No distant metastasis. (AJCC 8th ed.)


name: Basaloid squamous cell carcinoma of lung

description: A morphologic variant of squamous cell lung carcinoma characterized by nuclear palisading.


Stage IV Lung Cancer AJCC v8

description: Stage IV includes: IVA: (Any T, Any N, M1a); (Any T, Any N, M1b); IVB: (Any T, Any N, M1c). M1a: Tumor with separate tumor nodule(s) in a contralateral lobe; tumor with pleural or pericardial nodules or malignant pleural or pericardial effusion. Most pleural (pericardial) effusions with lung cancer are a result of the tumor. In a few patients, however, multiple microscopic examinations of pleural (pericardial) fluid are negative for tumor, and the fluid is nonbloody and not an exudate. If these elements and clinical judgment dictate that the effusion is not related to the tumor, the effusion should be excluded as a staging descriptor. M1b: Tumor with single extrathoracic metastasis in a single organ (including involvement of a single nonregional node). M1c: Tumor with multiple extrathoracic metastases in a single organ or in multiple organs. (AJCC 8th ed.)


name: Colorectal Carcinoma Metastatic in the Lung

description: A carcinoma that originates from the wall of the colon or rectum and has spread to the lungs.


name: Locally Advanced Lung Squamous Cell Carcinoma

description: Lung squamous cell carcinoma that has spread to nearly tissues or lymph nodes.


name: Stage IIIB Lung Squamous Cell Carcinoma AJCC v7

description: Stage IIIB includes: (T1a, N3, M0); (T1b, N3, M0); (T2a, N3, M0); (T2b, N3, M0); (T3, N3, M0); (T4, N2, M0); (T4, N3, M0).  T4: Lung cancer with a tumor of any size that invades any of the following: mediastinum, heart, great vessels, trachea, recurrent laryngeal nerve, esophagus, vertebral body, carina, and separate tumor nodule(s) in a different ipsilateral lobe.  N2: Lung cancer with metastasis to ipsilateral mediastinal and/or subcarinal lymph nodes.  N3: Lung cancer with metastasis to contralateral mediastinal, contralateral hilar, ipsilateral or contralateral scalene, or supraclavicular lymph nodes.  M0: No distant metastasis. (AJCC 7th ed.)


Pulmonary Artery Intimal Sarcoma

description: A sarcoma arising from the arterial intima of pulmonary arteries.


Advanced Lung Small Cell Carcinoma

description: Small cell lung carcinoma that has spread extensively to other anatomic sites or is no longer responding to treatment.


Lung Small Cell Carcinoma, Y Subtype

description: A molecular subtype of lung small cell carcinoma characterized by the overexpression of yes-associated protein 1 (YAP1) transcription factor.


name: Transformed EGFR-Positive Lung Adenocarcinoma to Small Cell Carcinoma

description: Histologic transformation of EGFR mutation-positive lung adenocarcinoma to small cell carcinoma, following treatment with tyrosine kinase inhibitors.


Stage IB Lung Cancer AJCC v8

description: Stage IB includes: T2a, N0, M0. T2a: Tumor measuring more than 3 cm but 4 cm or less in greatest dimension. N0: No regional lymph node metastases. M0: No distant metastasis. (AJCC 8th ed.)


name: Refractory Lung Non-Small Cell Carcinoma

description: Non-small cell lung carcinoma that does not respond to treatment.


name: Lung Small Cell Carcinoma, Neuroendocrine-Low Subtype

description: Lung small cell carcinoma characterized by low expression pattern of different neuroendocrine markers such as chromogranin A, synaptophysin, neural cell adhesion molecule 1, and gastrin-releasing peptide. It is associated with increased numbers of infiltrating immune cells (immune oasis phenotype).


Lung squamous cell carcinoma stage II

description: Stage II includes: IIA (T2b, N0, M0); (T1a, N1, M0); (T1b, N1, M0); (T2a, N1, M0) and IIB (T2b, N1, M0); (T3, N0, M0).  T2b: Lung cancer with a tumor size more than 5 cm but 7 cm or less in greatest dimension.  T1a: Lung cancer with a tumor size of 2 cm or less in greatest dimension, surrounded by lung or visceral pleura and without bronchoscopic evidence of invasion more proximal than the lobar bronchus (i.e., not in the main bronchus). The uncommon superficial tumor of any size with its invasive component limited to the bronchial wall, which may extend proximal to the main bronchus, is also classified as T1a.  T1b: Lung cancer with a tumor size more than 2 cm but 3 cm or less in greatest dimension, surrounded by lung or visceral pleura and without bronchoscopic evidence of invasion more proximal than the lobar bronchus (i.e., not in the main bronchus).  T2a: Lung cancer with a tumor size more than 3 cm but 5 cm or less in greatest dimension.  T3: Lung cancer with a tumor size more than 7 cm or one that directly invades any of the following: parietal pleural (PL3) chest wall (including superior sulcus tumors), diaphragm, phrenic nerve, mediastinal pleura, parietal pericardium; or tumor in the main bronchus (less than 2 cm distal to the carina but without involvement of the carina); or associated atelectasis or obstructive pneumonitis of the entire lung or separate tumor nodule(s) in the same lobe. N0: No regional lymph node metastasis.  N1: Lung cancer with metastasis in ipsilateral peribronchial and/or ipsilateral hilar lymph nodes and intrapulmonary lymph nodes, including involvement by direct extension. M0: No distant metastasis. (AJCC 7th ed.)


Resectable Lung Carcinoma

description: Lung carcinoma that is amenable to surgical resection.


name: Unresectable Lung Neuroendocrine Neoplasm

description: A lung neuroendocrine neoplasm that is not amenable to surgical resection.


Childhood Lung Non-Small Cell Carcinoma

description: A rare non-small cell carcinoma of the lung that occurs during childhood.


Locally Advanced Lung Adenocarcinoma

description: Lung adenocarcinoma that has spread from its original site of growth to nearby tissues or lymph nodes.


name: Stage IIB Lung Squamous Cell Carcinoma AJCC v7

description: Stage IIB includes: (T2b, N1, M0); (T3, N0, M0).  T2b: Lung cancer with a tumor size more than 5 cm but 7 cm or less in greatest dimension.  T3: Lung cancer with a tumor size more than 7 cm or one that directly invades any of the following: parietal pleural (PL3) chest wall (including superior sulcus tumors), diaphragm, phrenic nerve, mediastinal pleura, parietal pericardium; or tumor in the main bronchus (less than 2 cm distal to the carina but without involvement of the carina); or associated atelectasis or obstructive pneumonitis of the entire lung or separate tumor nodule(s) in the same lobe. N0: No regional lymph node metastasis.  N1: Lung cancer with metastasis in ipsilateral peribronchial and/or ipsilateral hilar lymph nodes and intrapulmonary lymph nodes, including involvement by direct extension. M0: No distant metastasis. (AJCC 7th ed.)


name: Prostate Carcinoma Metastatic in the Lung

description: A carcinoma that arises from the prostate gland and has spread to the lungs.


Lung Small Cell Carcinoma, I Subtype

description: A molecular subtype of lung small cell carcinoma characterized by the low expression of achaete-scute homolog 1 (ASCL1), neurogenic differentiation factor 1 (NEUROD1), and POU class 2 homeobox 3 (POU2F3) transcription factor signatures and elevated inflammatory gene signature expression.


Refractory Lung Adenocarcinoma

description: Lung adenocarcinoma that is resistant to treatment.


Stage IA Lung Adenocarcinoma AJCC v7

description: Stage IA includes: (T1a, N0, M0); (T1b, N0, M0).  T1a: Lung cancer with a tumor size of 2 cm or less in greatest dimension, surrounded by lung or visceral pleura and without bronchoscopic evidence of invasion more proximal than the lobar bronchus (i.e., not in the main bronchus). The uncommon superficial tumor of any size with its invasive component limited to the bronchial wall, which may extend proximal to the main bronchus, is also classified as T1a.  T1b: Lung cancer with a tumor size more than 2 cm but 3 cm or less in greatest dimension, surrounded by lung or visceral pleura and without bronchoscopic evidence of invasion more proximal than the lobar bronchus (i.e., not in the main bronchus).  N0: No regional lymph metastasis.  M0: No distant metastasis. (AJCC 7th ed.)


name: Stage I Lung Small Cell Carcinoma AJCC v7

description: Stage I includes: IA: (T1a, N0, M0); (T1b, N0, M0) and IB: (T2a, N0, M0).  T1a: Lung cancer with a tumor size of 2 cm or less n greatest dimension, surrounded by lung or visceral pleura and without bronchoscopic evidence of invasion more proximal than the lobar bronchus (i.e., not in the main bronchus). The uncommon superficial tumor of any size with its invasive component limited to the bronchial wall, which may extend proximal to the main bronchus, is also classified as T1a.  T1b: Lung cancer with a tumor size more than 2 cm but 3 cm or less in greatest dimension, surrounded by lung or visceral pleura and without bronchoscopic evidence of invasion more proximal than the lobar bronchus (i.e., not in the main bronchus).  T2a: Lung cancer with a tumor size more than 3 cm but 5 cm or less in greatest dimension.  N0: No regional lymph metastasis.  M0: No distant metastasis. (AJCC 7th ed.)


Occult Lung Non-Small Cell Carcinoma

description: A non-small cell lung carcinoma detectable by sputum cytology only.  The primary tumor is undetectable radiographically or during bronchoscopy; therefore, it can not be assessed.


name: Stage IIIB Lung Small Cell Carcinoma with Pleural Effusion AJCC v7

description: Stage IIIB small cell lung carcinoma that has spread to the pleural fluid.


Secondary malignant neoplasm of lung

description: The spread of a malignant neoplasm to the lung. This may be from a primary lung malignant neoplasm, or from a malignant neoplasm at a distant site.


Lung Synovial Sarcoma

description: A synovial sarcoma arising from the lungs.


name: Non-mucinous adenocarcinoma in situ of lung

description: Lung adenocarcinoma in situ characterized by the presence of type II pneumocyte and/or Clara cell differentiation. Almost all cases of lung adenocarcinoma in situ are non-mucinous.


Lung Mucinous Adenocarcinoma In Situ

description: A very rare lung adenocarcinoma in situ variant characterized by the presence of tall columnar cells with basal nuclei and abundant cytoplasmic mucin.


Adenocarcinoma of lung, stage IV

description: Stage IV includes: (Any T, Any N, M1a); (Any T, Any N, M1b).  M1a: Lung cancer with separate tumor nodule(s) in a contralateral lobe; tumor with pleural nodules or malignant pleural (or pericardial) effusion.  M1b: Distant metastasis. (AJCC 7th ed.)


name: Metastatic Lung Non-Small Cell Carcinoma

description: A non-small cell carcinoma that arises from the lung and has metastasized to another anatomic site.


name: Combined Lung Small Cell Carcinoma and Lung Adenocarcinoma

description: A lung carcinoma characterized by a combination of small cell carcinoma and adenocarcinoma.


Lung squamous cell carcinoma stage III

description: Stage III includes: IIIA (T1a, N2, M0); (T1b, N2, M0); (T2a, N2, M0); (T2b, N2, M0); (T3, N1, M0); (T3, N2, M0); (T4, N0, M0); (T4, N1, M0) and IIIB (T1a, N3, M0); (T1b, N3, M0); (T2a, N3, M0); (T2b, N3, M0); (T3, N3, M0); (T4, N2, M0); (T4, N3, M0).  T4: Lung cancer with a tumor of any size that invades any of the following: mediastinum, heart, great vessels, trachea, recurrent laryngeal nerve, esophagus, vertebral body, carina, and separate tumor nodule(s) in a different ipsilateral lobe.  N1: Lung cancer with metastasis in ipsilateral peribronchial and/or ipsilateral hilar lymph nodes and intrapulmonary lymph nodes, including involvement by direct extension.  N2: Lung cancer with metastasis to ipsilateral mediastinal and/or subcarinal lymph nodes.  N3: Lung cancer with metastasis to contralateral mediastinal, contralateral hilar, ipsilateral or contralateral scalene, or supraclavicular lymph nodes.  M0: No distant metastasis. (AJCC 7th ed.)


name: Metastatic Lung Non-Small Cell Squamous Carcinoma

description: A squamous non-small cell carcinoma that arises from the lung and has metastasized to another anatomic site.


name: Unresectable Lung Neuroendocrine Carcinoma

description: Lung neuroendocrine carcinoma that is not amenable to surgical resection.


name: Locally Advanced Lung Non-Small Cell Squamous Carcinoma

description: A non-small cell squamous carcinoma of the lung that has spread from its original site of growth to nearby tissues or lymph nodes.


name: Transformed EGFR-Positive Lung Non-Small Cell Carcinoma to Small Cell Carcinoma

description: Histologic transformation of EGFR mutation-positive lung non-small cell carcinoma to small cell carcinoma, following treatment with tyrosine kinase inhibitors.


Lung Cancer by AJCC v6 Stage

description: A term that refers to the staging of lung carcinoma according to the American Joint Committee on Cancer, 6th edition.


name: Lung Carcinoma Metastatic in the Central Nervous System

description: A carcinoma that has spread to the central nervous system from its original site in the lung, through the hematogenous route.


Stage II Lung Cancer AJCC v6

description: Stage II includes: IIA (T1, N1, M0) and IIB (T2, N1, M0) or (T3, N0, M0).  T1: Tumor is 3 cm or less in greatest dimension, surrounded by lung or visceral pleura, and without bronchoscopic evidence of invasion more proximal than the lobar bronchus.  T2: Tumor has any of the following features of size or extent: more than 3 cm in greatest dimension; involves the main bronchus, 2 cm or more distal to the carina; invades the visceral pleura; associated with atelectasis or obstructive pneumonitis that extends to the hilar region but does not involve the entire lung.  T3: Tumor (of any size) directly invades any of the following: chest wall (including superior sulcus tumors), diaphragm, mediastinal pleura, parietal pericardium; or tumor in the main bronchus less than 2 cm distal to the carina but without involvement of the carina; or associated atelectasis or obstructive pneumonitis of the entire lung. N0: No regional lymph node metastasis.  N1: Metastasis to ipsilateral peribronchial and/or ipsilateral hilar lymph nodes, and intrapulmonary nodes including involvement by direct extension of the primary tumor. M0: No distant metastasis. (AJCC 6th ed.)


name: Stage IV Lung Small Cell Carcinoma AJCC v7


name: Refractory Lung Non-Squamous Non-Small Cell Carcinoma

description: Non-squamous non-small cell lung carcinoma that is resistant to treatment.


Lung Small Cell Carcinoma, P Subtype

description: A molecular subtype of lung small cell carcinoma characterized by the overexpression of POU class 2 homeobox 3 (POU2F3) transcription factor.


Stage III Lung Cancer AJCC v8

description: Stage III includes: IIIA: (T1a, N2, M0); (T1b, N2, M0); (T1c, N2, M0); (T2a, N2, M0); (T2b, N2, M0); (T3, N1, M0); (T4, N0, M0); (T4, N1, M0); IIIB: (T1a, N3, M0); (T1b, N3, M0); (T1c, N3, M0); (T2a, N3, M0); (T2b, N3, M0); (T3, N2, M0); (T4, N2, M0); IIIC: (T3, N3, M0); (T4, N3, M0). T1a: Tumor measuring 1 cm or less in greatest dimension. A superficial, spreading tumor of any size whose invasive component is limited to the bronchial wall and may extend proximal to the main bronchus also is classified as T1a, but these tumors are uncommon. T1b: Tumor measuring more than 1 cm but 2 cm or less in greatest dimension. T1c: Tumor measuring more than 2 cm but 3 cm or less in greatest dimension. T2a: Tumor measuring more than 3 cm but 4 cm or less in greatest dimension. T2b: Tumor measuring more than 4 cm but 5 cm or less in greatest dimension. T3: Tumor measuring more than 5 cm but 7 cm or less in greatest dimension or directly invading any of the following: parietal pleura (PL3), chest wall (including superior sulcus tumors), phrenic nerve, parietal pericardium; or separate tumor nodule(s) in the same lobe as the primary. T4: Tumor measuring more than 7 cm or tumor of any size invading one or more of the following: diaphragm, mediastinum, heart, great vessels, trachea, recurrent laryngeal nerve, esophagus, vertebral body, or carina; separate tumor nodule(s) in an ipsilateral lobe different from that of the primary. N0: No regional lymph node metastases. N1: Metastasis in ipsilateral peribronchial and/or ipsilateral hilar lymph nodes and intrapulmonary nodes, including involvement by direct extension. N2: Metastasis in ipsilateral mediastinal and/or subcarinal lymph node(s). N3: Metastasis in contralateral mediastinal, contralateral hilar, ipsilateral or contralateral scalene, or supraclavicular lymph node(s). M0: No distant metastasis. (AJCC 8th ed.)


Adenocarcinoma of lung, stage I

description: Stage I includes: IA: (T1a, N0, M0); (T1b, N0, M0) and IB: (T2a, N0, M0).  T1a: Lung cancer with a tumor size of 2 cm or less n greatest dimension, surrounded by lung or visceral pleura and without bronchoscopic evidence of invasion more proximal than the lobar bronchus (i.e., not in the main bronchus). The uncommon superficial tumor of any size with its invasive component limited to the bronchial wall, which may extend proximal to the main bronchus, is also classified as T1a.  T1b: Lung cancer with a tumor size more than 2 cm but 3 cm or less in greatest dimension, surrounded by lung or visceral pleura and without bronchoscopic evidence of invasion more proximal than the lobar bronchus (i.e., not in the main bronchus).  T2a: Lung cancer with a tumor size more than 3 cm but 5 cm or less in greatest dimension.  N0: No regional lymph metastasis.  M0: No distant metastasis. (AJCC 7th ed.)


carcinosarcoma of lung

description: A morphologic variant of lung sarcomatoid carcinoma composed of a mixture of non-small cell lung carcinoma and a sarcomatous component.


name: Lung Squamous Cell Carcinoma, Clear Cell Variant

description: A morphologic variant of squamous cell lung carcinoma characterized by the presence of clear cells.


constitutional neutropenia

description: A rare disorder characterized by recurrent infantile infections and absence of neutrophils in the peripheral blood.


name: lipoyl amidotransferase LIPT1, mitochondrial phosphorylated 1 (human)

description: A lipoyl amidotransferase LIPT1, mitochondrial (human) that has been phosphorylated on the residue at the position equivalent to Ser-191 of the amino acid sequence represented by UniProtKB:Q9Y234. UniProtKB:Q9Y234, Ser-191, MOD:00046.


name: ribonucleoside-diphosphate reductase large subunit isoform 1 (human)

description: A ribonucleoside-diphosphate reductase large subunit isoform 1 that is encoded in the genome of human.


name: ribonucleoside-diphosphate reductase large subunit methylated 2 (human)

description: A ribonucleoside-diphosphate reductase large subunit (human) that has been methylated on the residue at the position equivalent to Cys-429 of the amino acid sequence represented by UniProtKB:P23921. UniProtKB:P23921, Cys-429, MOD:00660.


name: ribonucleoside-diphosphate reductase large subunit deaminated 2 (human)

description: A ribonucleoside-diphosphate reductase large subunit (human) that has been deaminated on the residue at the position equivalent to Gln-530 of the amino acid sequence represented by UniProtKB:P23921. UniProtKB:P23921, Gln-530, MOD:00685.


name: ribonucleoside-diphosphate reductase large subunit methylated 1 (human)

description: A ribonucleoside-diphosphate reductase large subunit (human) that has been methylated on the residue at the position equivalent to Cys-26 of the amino acid sequence represented by UniProtKB:P23921. UniProtKB:P23921, Cys-26, MOD:00660.


name: ribonucleoside-diphosphate reductase large subunit cysteinylated 2 (human)

description: A ribonucleoside-diphosphate reductase large subunit (human) that has been cysteinylated on the residue at the position equivalent to Cys-444 of the amino acid sequence represented by UniProtKB:P23921. UniProtKB:P23921, Cys-444, MOD:00765.


name: ribonucleoside-diphosphate reductase large subunit deaminated 1 (human)

description: A ribonucleoside-diphosphate reductase large subunit (human) that has been deaminated on the residue at the position equivalent to Asn-85 of the amino acid sequence represented by UniProtKB:P23921. UniProtKB:P23921, Asn-85, MOD:00684.


name: ribonucleoside-diphosphate reductase large subunit deaminated 3 (human)

description: A ribonucleoside-diphosphate reductase large subunit (human) that has been deaminated on the residue at the position equivalent to Gln-678 of the amino acid sequence represented by UniProtKB:P23921. UniProtKB:P23921, Gln-678, MOD:00685.


name: ribonucleoside-diphosphate reductase large subunit cysteinylated 1 (human)

description: A ribonucleoside-diphosphate reductase large subunit (human) that has been cysteinylated on the residue at the position equivalent to Cys-26 of the amino acid sequence represented by UniProtKB:P23921. UniProtKB:P23921, Cys-26, MOD:00765.